<![CDATA[GiHF Medcast]]>ee71a2db-1024-5a21-b255-a5c31d91e5d5Tue, 23 Sep 2025 04:00:27 +0000Captivate.fmThe Gi Health Foundation https://artwork.captivate.fm/904e1858-f00f-4e3b-bc09-059b75ff5108/lmUbUkloJIiRwLYCdnPy8BDt.jpegGiHF MedcastThe Gi Health Foundation The Gi Health Foundation The official podcast channel for the GI Health Foundation. GiHF Medcast delivers expert-led conversations, clinical insights, and the latest in gastroenterology. Designed for healthcare professionals, each episode explores evidence-based strategies and emerging research to elevate patient care. The Gi Health Foundation is a nonprofit 501(c)(3) educational organization dedicated to increasing awareness of the effect of gastrointestinal disorders in the United States. The foundation's goal is to provide health professionals with the most current education and information on gastrointestinal health.https://gihealthfoundation.org/index.cfmfalseepisodicnopodcastKOL Conversation: Making Sense of Carbohydrate MaldigestionKOL Conversation: Making Sense of Carbohydrate MaldigestionAt GI ReConnect, Dr. Dakesh Patel and registered dietitian Kate Scarlata dive into the overlooked role of carbohydrate maldigestion, malabsorption, and intolerance in patients experiencing common gastrointestinal symptoms such as gas, bloating, abdominal pain, and diarrhea. Drawing on their recent publication in the American Journal of Gastroenterology, they break down how deficiencies in enzymes like lactase, sucrase, maltase, and isomaltase can disrupt carbohydrate breakdown and trigger IBS-like symptoms. The discussion explores the distinctions between maldigestion, malabsorption, and intolerance, the influence of gut microbiota, and the importance of considering carbohydrate intolerance as a trigger for IBS. They also highlight emerging diagnostic approaches, the role of diet—including low-FODMAP strategies—and enzyme replacement therapies to improve patient outcomes while maintaining nutritional balance. Whether you’re a gastroenterologist, dietitian, or patient seeking to understand the science behind carbohydrate intolerance, this session offers practical insights into managing digestive health.

]]>At GI ReConnect, Dr. Dakesh Patel and registered dietitian Kate Scarlata dive into the overlooked role of carbohydrate maldigestion, malabsorption, and intolerance in patients experiencing common gastrointestinal symptoms such as gas, bloating, abdominal pain, and diarrhea. Drawing on their recent publication in the American Journal of Gastroenterology, they break down how deficiencies in enzymes like lactase, sucrase, maltase, and isomaltase can disrupt carbohydrate breakdown and trigger IBS-like symptoms. The discussion explores the distinctions between maldigestion, malabsorption, and intolerance, the influence of gut microbiota, and the importance of considering carbohydrate intolerance as a trigger for IBS. They also highlight emerging diagnostic approaches, the role of diet—including low-FODMAP strategies—and enzyme replacement therapies to improve patient outcomes while maintaining nutritional balance. Whether you’re a gastroenterologist, dietitian, or patient seeking to understand the science behind carbohydrate intolerance, this session offers practical insights into managing digestive health.

]]>c5803069-c561-4055-a342-d8d377165ed4Tue, 23 Sep 2025 00:00:00 -040024:56falsefullKOL Conversation From Peds Connect on IBDKOL Conversation From Peds Connect on IBDJoin leading pediatric IBD experts Dr. Joel Rosh, Cohen Children’s Medical Center, Dr. Sandra Kim, Cleveland Clinic, Dr. Judith Kelson, Children’s Hospital of Philadelphia, and Dr. Jeffrey Hyams, Connecticut Children’s Medical Center, for an in-depth roundtable on the complexities of diagnosing and managing inflammatory bowel disease in children and teens. With over a century of combined clinical experience, the panel shares insights on second opinions, avoiding misdiagnosis, optimizing biologic therapy, therapeutic drug monitoring, and addressing pitfalls such as underdosing. They also explore the role of diet and nutrition in Crohn’s disease and ulcerative colitis, navigating vaccination challenges in VEO-IBD, and integrating psychosocial support for patients and families. This candid conversation offers practical pearls for gastroenterologists, pediatricians, and multidisciplinary teams seeking to improve outcomes and quality of life for pediatric IBD patients.

#PediatricIBD #CrohnsDisease #UlcerativeColitis #VEOIBD #IBDTreatment #BiologicTherapy #TherapeuticDrugMonitoring #PediatricGastroenterology #SecondOpinion #CrohnsDiet #UlcerativeColitisDiet #PsychosocialSupport #ChildrensHealth #IBDCare #MedicalRoundtable

]]>Join leading pediatric IBD experts Dr. Joel Rosh, Cohen Children’s Medical Center, Dr. Sandra Kim, Cleveland Clinic, Dr. Judith Kelson, Children’s Hospital of Philadelphia, and Dr. Jeffrey Hyams, Connecticut Children’s Medical Center, for an in-depth roundtable on the complexities of diagnosing and managing inflammatory bowel disease in children and teens. With over a century of combined clinical experience, the panel shares insights on second opinions, avoiding misdiagnosis, optimizing biologic therapy, therapeutic drug monitoring, and addressing pitfalls such as underdosing. They also explore the role of diet and nutrition in Crohn’s disease and ulcerative colitis, navigating vaccination challenges in VEO-IBD, and integrating psychosocial support for patients and families. This candid conversation offers practical pearls for gastroenterologists, pediatricians, and multidisciplinary teams seeking to improve outcomes and quality of life for pediatric IBD patients.

#PediatricIBD #CrohnsDisease #UlcerativeColitis #VEOIBD #IBDTreatment #BiologicTherapy #TherapeuticDrugMonitoring #PediatricGastroenterology #SecondOpinion #CrohnsDiet #UlcerativeColitisDiet #PsychosocialSupport #ChildrensHealth #IBDCare #MedicalRoundtable

]]>65264e82-e630-4ec3-9b5e-59ab6608a889Wed, 06 Aug 2025 00:00:00 -040030:38falsefullKOL Conversation With a Focus on MotilityKOL Conversation With a Focus on MotilityJoin Dr. Peter Lu, from The Ohio State University College of Medicine, and Dr. Miguel Saps, a renowned pediatric neurogastroenterologist and motility expert from the University of Miami, as they dive deep into the evaluation and management of pediatric constipation—a condition affecting nearly 10% of children. Filmed live at the second Pediatric GI Connect meeting in Hollywood, Florida, this comprehensive discussion covers evidence-based natural remedies, the role of water, fiber, probiotics, and fruit juices, as well as the latest on pharmacologic therapies including polyethylene glycol (PEG 3350), senna, and bisacodyl. The conversation also addresses common parental concerns around stimulant laxatives and PEG safety, referencing recent data on metabolite levels and long-term outcomes. New and emerging therapies such as linaclotide, prucalopride, and even vibratory capsules and neuromodulation techniques are explored as promising options for refractory constipation. Whether you're a pediatric GI specialist, general pediatrician, or a caregiver seeking clarity, this evidence-rich episode delivers up-to-date insights into the evolving landscape of childhood constipation treatment.

]]>Join Dr. Peter Lu, from The Ohio State University College of Medicine, and Dr. Miguel Saps, a renowned pediatric neurogastroenterologist and motility expert from the University of Miami, as they dive deep into the evaluation and management of pediatric constipation—a condition affecting nearly 10% of children. Filmed live at the second Pediatric GI Connect meeting in Hollywood, Florida, this comprehensive discussion covers evidence-based natural remedies, the role of water, fiber, probiotics, and fruit juices, as well as the latest on pharmacologic therapies including polyethylene glycol (PEG 3350), senna, and bisacodyl. The conversation also addresses common parental concerns around stimulant laxatives and PEG safety, referencing recent data on metabolite levels and long-term outcomes. New and emerging therapies such as linaclotide, prucalopride, and even vibratory capsules and neuromodulation techniques are explored as promising options for refractory constipation. Whether you're a pediatric GI specialist, general pediatrician, or a caregiver seeking clarity, this evidence-rich episode delivers up-to-date insights into the evolving landscape of childhood constipation treatment.

]]>4272af04-fe35-4ae3-81ce-8806a80f8a27Tue, 24 Jun 2025 00:00:00 -040019:35falsefullKOL Conversation With a Focus on EoEKOL Conversation With a Focus on EoEIn this episode recorded at the second annual Peds GI Connect, pediatric gastroenterologists Dr. Amanda Muir, Children’s Hospital of Philadelphia, Dr. Rajitha Venkatesh, Nationwide Children’s Hospital, and Dr. Umber Langshaw, University of Miami, engage in a thoughtful discussion on eosinophilic esophagitis (EoE)—from updated diagnostic guidelines to innovative, patient-centered approaches. They highlight the 2023 ACG Guidelines, which emphasize the importance of obtaining six esophageal biopsies from multiple levels, even when the mucosa appears normal. Drawing on both clinical expertise and personal experience, the conversation covers variability in symptom presentation, barriers to diagnosis, and the psychological burden of repeated procedures in children. The trio also explores emerging tools like transnasal endoscopy, string testing, and non-sedated biopsy methods, examining how these techniques may reduce procedural stress and improve monitoring over time. With real-life case insights, discussion on treatment monitoring, and the evolving EoE care landscape, this episode is a must-watch for clinicians, caregivers, and researchers seeking a comprehensive update on eosinophilic esophagitis in pediatrics.

]]>In this episode recorded at the second annual Peds GI Connect, pediatric gastroenterologists Dr. Amanda Muir, Children’s Hospital of Philadelphia, Dr. Rajitha Venkatesh, Nationwide Children’s Hospital, and Dr. Umber Langshaw, University of Miami, engage in a thoughtful discussion on eosinophilic esophagitis (EoE)—from updated diagnostic guidelines to innovative, patient-centered approaches. They highlight the 2023 ACG Guidelines, which emphasize the importance of obtaining six esophageal biopsies from multiple levels, even when the mucosa appears normal. Drawing on both clinical expertise and personal experience, the conversation covers variability in symptom presentation, barriers to diagnosis, and the psychological burden of repeated procedures in children. The trio also explores emerging tools like transnasal endoscopy, string testing, and non-sedated biopsy methods, examining how these techniques may reduce procedural stress and improve monitoring over time. With real-life case insights, discussion on treatment monitoring, and the evolving EoE care landscape, this episode is a must-watch for clinicians, caregivers, and researchers seeking a comprehensive update on eosinophilic esophagitis in pediatrics.

]]>b13df11c-cefc-4577-a8cc-4f1399003214Tue, 24 Jun 2025 00:00:00 -040013:23falsefullKOL Conversation With a Focus on NutritionKOL Conversation With a Focus on NutritionIn this special episode from the second annual Peds GI Connect conference, four leading pediatric gastroenterologists—Dr. Valeria Cohran, Lurie Children's Hospital, Dr. Praveen Goday, Nationwide Children’s Hospital, Dr. Chris Duggan, Boston Children’s Hospital/Harvard Medical School, and Dr. Maria Mascarenhas, Children's Hospital of Philadelphia—come together to discuss their journeys into the field of pediatric nutrition and why it remains a vital, dynamic, and underexplored aspect of GI care. From intestinal rehabilitation and clinical nutrition programs to global health, culinary medicine, and parenteral nutrition safety, this roundtable highlights the vast and meaningful career opportunities available in pediatric nutrition. The panel emphasizes the importance of physician involvement in nutrition decisions, collaborative care with dietitians, and the urgent need to improve nutrition education during medical training. With perspectives spanning decades and institutions, they call for a new generation of GI fellows to lead in nutrition research, advocacy, and hospital-based nutrition leadership. Whether you're a trainee, clinician, or medical educator, this is a must-watch conversation about shaping the future of pediatric nutrition.

]]>In this special episode from the second annual Peds GI Connect conference, four leading pediatric gastroenterologists—Dr. Valeria Cohran, Lurie Children's Hospital, Dr. Praveen Goday, Nationwide Children’s Hospital, Dr. Chris Duggan, Boston Children’s Hospital/Harvard Medical School, and Dr. Maria Mascarenhas, Children's Hospital of Philadelphia—come together to discuss their journeys into the field of pediatric nutrition and why it remains a vital, dynamic, and underexplored aspect of GI care. From intestinal rehabilitation and clinical nutrition programs to global health, culinary medicine, and parenteral nutrition safety, this roundtable highlights the vast and meaningful career opportunities available in pediatric nutrition. The panel emphasizes the importance of physician involvement in nutrition decisions, collaborative care with dietitians, and the urgent need to improve nutrition education during medical training. With perspectives spanning decades and institutions, they call for a new generation of GI fellows to lead in nutrition research, advocacy, and hospital-based nutrition leadership. Whether you're a trainee, clinician, or medical educator, this is a must-watch conversation about shaping the future of pediatric nutrition.

]]>d4a85450-aff8-4cfe-a3b6-9218865259c1Tue, 24 Jun 2025 00:00:00 -040021:07falsefullKOL Conversation With a Focus on CSIDKOL Conversation With a Focus on CSIDIn this engaging episode recorded at the second annual Peds GI Connect in Hollywood, Florida, Dr. Carlo Di Lorenzo, pediatric gastroenterologist at Nationwide Children’s Hospital, is joined by Kate Scarlata, MPH, RDN, and Dr. Ankur Chugh from Children’s Wisconsin for a deep dive into sucrase-isomaltase deficiency (SID)—a condition gaining traction in both clinical and public awareness. Together, they explore how SID, previously thought to be rare and limited to congenital forms, is increasingly recognized in both children and adults as a contributor to unexplained gastrointestinal symptoms like bloating, gas, diarrhea, and abdominal pain. The discussion breaks down diagnostic tools—from disaccharidase enzyme assays to the sucrose challenge—and outlines the nuances of dietary management, enzyme therapy, and the role of registered dietitians in tailoring treatment. The episode also highlights how SID can mimic IBS or DGBI and emphasizes the importance of avoiding overly restrictive diets in children. With real-world insights, practical tips, and a shared decision-making approach, this conversation is essential for clinicians, dietitians, and caregivers interested in the evolving landscape of carbohydrate digestion disorders and personalized GI care.

]]>In this engaging episode recorded at the second annual Peds GI Connect in Hollywood, Florida, Dr. Carlo Di Lorenzo, pediatric gastroenterologist at Nationwide Children’s Hospital, is joined by Kate Scarlata, MPH, RDN, and Dr. Ankur Chugh from Children’s Wisconsin for a deep dive into sucrase-isomaltase deficiency (SID)—a condition gaining traction in both clinical and public awareness. Together, they explore how SID, previously thought to be rare and limited to congenital forms, is increasingly recognized in both children and adults as a contributor to unexplained gastrointestinal symptoms like bloating, gas, diarrhea, and abdominal pain. The discussion breaks down diagnostic tools—from disaccharidase enzyme assays to the sucrose challenge—and outlines the nuances of dietary management, enzyme therapy, and the role of registered dietitians in tailoring treatment. The episode also highlights how SID can mimic IBS or DGBI and emphasizes the importance of avoiding overly restrictive diets in children. With real-world insights, practical tips, and a shared decision-making approach, this conversation is essential for clinicians, dietitians, and caregivers interested in the evolving landscape of carbohydrate digestion disorders and personalized GI care.

]]>5eda4d51-d6ff-44af-b73f-9a0c4cf321b9Tue, 24 Jun 2025 00:00:00 -040028:25falsefullKOL Conversation on C. difficileKOL Conversation on C. difficileJoin Dr. Paul Feuerstadt, along with Dr. Darrell Pardi and Dr. Sahil Khanna from the Mayo Clinic, for a timely and in-depth discussion on Clostridioides difficile (C. difficile) infection, recorded live at GI ReConnect in Denver. In this expert roundtable, the panel explores shifting epidemiology trends, the evolution of diagnostic testing algorithms, and best practices for managing both initial and recurrent C. diff cases. They weigh the clinical impact of the discontinuation of bezlotoxumab, discuss updated treatment strategies—including fidaxomicin use and the role of extended-pulsed regimens—and examine the emerging use of FDA-approved microbiome restoration therapies such as REBYOTA® and VOWST®. With practical insights on interpreting discordant toxin assays, managing high-risk or immunocompromised patients, and addressing fulminant cases in critical care, this conversation offers gastroenterologists, infectious disease specialists, and primary care providers essential guidance on navigating an increasingly complex therapeutic landscape. The group also addresses the implications of OpenBiome's closure, the promise of cost-effective options as fidaxomicin nears patent expiration, and the importance of individualized, risk-based care in preventing recurrence and improving outcomes.

]]>Join Dr. Paul Feuerstadt, along with Dr. Darrell Pardi and Dr. Sahil Khanna from the Mayo Clinic, for a timely and in-depth discussion on Clostridioides difficile (C. difficile) infection, recorded live at GI ReConnect in Denver. In this expert roundtable, the panel explores shifting epidemiology trends, the evolution of diagnostic testing algorithms, and best practices for managing both initial and recurrent C. diff cases. They weigh the clinical impact of the discontinuation of bezlotoxumab, discuss updated treatment strategies—including fidaxomicin use and the role of extended-pulsed regimens—and examine the emerging use of FDA-approved microbiome restoration therapies such as REBYOTA® and VOWST®. With practical insights on interpreting discordant toxin assays, managing high-risk or immunocompromised patients, and addressing fulminant cases in critical care, this conversation offers gastroenterologists, infectious disease specialists, and primary care providers essential guidance on navigating an increasingly complex therapeutic landscape. The group also addresses the implications of OpenBiome's closure, the promise of cost-effective options as fidaxomicin nears patent expiration, and the importance of individualized, risk-based care in preventing recurrence and improving outcomes.

]]>aaa36ee2-4eef-443c-b6f5-821d1fa0bcbbMon, 23 Jun 2025 00:00:00 -040023:51falsefullKOL Conversation on IBDKOL Conversation on IBDJoin Dr. Russell Cohen, Professor of Medicine and Clinical Director of the IBD Center at the University of Chicago, and Dr. Parambir Dulai, Director of Precision Medicine at Northwestern University, for an in-depth discussion recorded live at the GI ReConnect Conference in Denver. In this expert-led podcast, the faculty review the evolving therapeutic landscape in inflammatory bowel disease (IBD), including novel and emerging drug classes such as IL-23 inhibitors, S1P modulators, JAK and TYK2 inhibitors, and anti-TL1A agents. Dr. Dulai outlines current strategies for combination therapy, highlights the challenges of therapeutic durability, and emphasizes the potential for small molecules to transform episodic management. The conversation explores precision medicine, the role of biomarkers, microbiome-targeted approaches, metabolic comorbidities, and cardiovascular risks in IBD. The faculty also touch on extraintestinal manifestations like arthritis and pyoderma gangrenosum, weighing how these impact treatment selection. This session is a must-watch for clinicians interested in optimizing long-term outcomes in Crohn’s disease and ulcerative colitis through early intervention, tailored therapy, and sustained disease control. Presented by GIHF, this episode reflects cutting-edge thinking at the forefront of IBD care.

]]>Join Dr. Russell Cohen, Professor of Medicine and Clinical Director of the IBD Center at the University of Chicago, and Dr. Parambir Dulai, Director of Precision Medicine at Northwestern University, for an in-depth discussion recorded live at the GI ReConnect Conference in Denver. In this expert-led podcast, the faculty review the evolving therapeutic landscape in inflammatory bowel disease (IBD), including novel and emerging drug classes such as IL-23 inhibitors, S1P modulators, JAK and TYK2 inhibitors, and anti-TL1A agents. Dr. Dulai outlines current strategies for combination therapy, highlights the challenges of therapeutic durability, and emphasizes the potential for small molecules to transform episodic management. The conversation explores precision medicine, the role of biomarkers, microbiome-targeted approaches, metabolic comorbidities, and cardiovascular risks in IBD. The faculty also touch on extraintestinal manifestations like arthritis and pyoderma gangrenosum, weighing how these impact treatment selection. This session is a must-watch for clinicians interested in optimizing long-term outcomes in Crohn’s disease and ulcerative colitis through early intervention, tailored therapy, and sustained disease control. Presented by GIHF, this episode reflects cutting-edge thinking at the forefront of IBD care.

]]>6e48f376-6d0d-4e4a-a9d5-7d9babd10888Mon, 23 Jun 2025 00:00:00 -040028:00falsefullKOL Conversation on AmyloidosisKOL Conversation on AmyloidosisIn this expert-led discussion from GI ReConnect, Dr. David Kunkel is joined by Dr. Lucinda Harris and Dr. Ali Rezaie to explore the evolving understanding of gastrointestinal involvement in amyloidosis. The panel unpacks how misfolded protein deposition can lead to a wide spectrum of GI symptoms—from diarrhea, weight loss, and gastroparesis to small intestinal bacterial overgrowth (SIBO), bleeding, and malnutrition. They walk through diagnostic strategies, including the importance of requesting Congo red staining during biopsy and maintaining a high index of suspicion in patients with unexplained GI symptoms, particularly those with systemic red flags. Real-world insights into multidisciplinary management—including collaboration with cardiology, hematology, nephrology, and neurology—highlight the systemic nature of amyloidosis and the need for early intervention. The panel also reviews emerging treatment options for AL, AA, and ATTR amyloidosis, emphasizing how timely diagnosis can prevent irreversible organ damage and dramatically improve outcomes. With personal reflections, practical pearls, and guidance for both clinicians and patients, this episode is a must-watch for gastroenterologists navigating complex, multisystem diseases.

]]>In this expert-led discussion from GI ReConnect, Dr. David Kunkel is joined by Dr. Lucinda Harris and Dr. Ali Rezaie to explore the evolving understanding of gastrointestinal involvement in amyloidosis. The panel unpacks how misfolded protein deposition can lead to a wide spectrum of GI symptoms—from diarrhea, weight loss, and gastroparesis to small intestinal bacterial overgrowth (SIBO), bleeding, and malnutrition. They walk through diagnostic strategies, including the importance of requesting Congo red staining during biopsy and maintaining a high index of suspicion in patients with unexplained GI symptoms, particularly those with systemic red flags. Real-world insights into multidisciplinary management—including collaboration with cardiology, hematology, nephrology, and neurology—highlight the systemic nature of amyloidosis and the need for early intervention. The panel also reviews emerging treatment options for AL, AA, and ATTR amyloidosis, emphasizing how timely diagnosis can prevent irreversible organ damage and dramatically improve outcomes. With personal reflections, practical pearls, and guidance for both clinicians and patients, this episode is a must-watch for gastroenterologists navigating complex, multisystem diseases.

]]>602c1099-c979-484b-b5ce-0fe60e3ad811Mon, 23 Jun 2025 00:00:00 -040021:49falsefullKOL Conversation on GERD, H. pylori, & GastroparesisKOL Conversation on GERD, H. pylori, & GastroparesisIn this dynamic and metaphor-rich discussion recorded at GI ReConnect, Dr. Braden Kuo, Dr. Kyle Staller, and Dr. David Kunkel—leaders in motility and upper GI care—explore the evolving landscape of gastroparesis management, acid suppression therapy, and H. pylori treatment. The conversation begins with a critical review of the draft AGA guidelines for gastroparesis, highlighting the controversy around conditional recommendations, the strict grading methodology, and the limited number of therapies (such as metoclopramide and erythromycin) that currently meet efficacy thresholds. The panel unpacks how these guidelines may affect clinical decision-making, insurance access, and shared decision-making conversations with patients. Transitioning to acid suppression, they introduce potassium-competitive acid blockers (PCABs) as a new, faster-acting class of medications that overcome some of the practical limitations of PPIs. The group shares real-world scenarios for using PCABs, from on-demand therapy to cases of nighttime reflux or partial PPI responders, while emphasizing the importance of diagnostic clarity via pH monitoring. Finally, they discuss the potential for PCABs to improve H. pylori eradication rates by enhancing antibiotic efficacy in a higher pH environment and simplifying regimens in the face of rising clarithromycin resistance and patient nonadherence. Whether you treat upper GI disorders, motility dysfunction, or functional dyspepsia, this episode offers practical pearls, forward-looking perspectives, and a call to action for improving research and outcomes in underfunded GI disease states.

]]>In this dynamic and metaphor-rich discussion recorded at GI ReConnect, Dr. Braden Kuo, Dr. Kyle Staller, and Dr. David Kunkel—leaders in motility and upper GI care—explore the evolving landscape of gastroparesis management, acid suppression therapy, and H. pylori treatment. The conversation begins with a critical review of the draft AGA guidelines for gastroparesis, highlighting the controversy around conditional recommendations, the strict grading methodology, and the limited number of therapies (such as metoclopramide and erythromycin) that currently meet efficacy thresholds. The panel unpacks how these guidelines may affect clinical decision-making, insurance access, and shared decision-making conversations with patients. Transitioning to acid suppression, they introduce potassium-competitive acid blockers (PCABs) as a new, faster-acting class of medications that overcome some of the practical limitations of PPIs. The group shares real-world scenarios for using PCABs, from on-demand therapy to cases of nighttime reflux or partial PPI responders, while emphasizing the importance of diagnostic clarity via pH monitoring. Finally, they discuss the potential for PCABs to improve H. pylori eradication rates by enhancing antibiotic efficacy in a higher pH environment and simplifying regimens in the face of rising clarithromycin resistance and patient nonadherence. Whether you treat upper GI disorders, motility dysfunction, or functional dyspepsia, this episode offers practical pearls, forward-looking perspectives, and a call to action for improving research and outcomes in underfunded GI disease states.

]]>9fe8b7b1-c2a2-431d-b756-58cb560a6b58Mon, 23 Jun 2025 00:00:00 -040029:06falsefullKOL Conversation on EOEKOL Conversation on EOEJoin Dr. Amit Patel and Dr. Gary Falk as they recap key highlights from the Eosinophilic Esophagitis (EoE) Disease State Summit, held live at GI ReConnect in Colorado. This expert-led discussion explores best practices in the evaluation, diagnosis, and management of EoE. The panel emphasizes updates from the ACG guidelines, including the importance of performing index endoscopy off therapy, standardized scoring tools like EREFS and the EoE Index of Severity (EoE-IS), and the nuanced role of histology in guiding treatment. They discuss differentiating EoE from GERD, appropriate biopsy practices, and integrating pathology features such as lamina propria fibrosis and microabscesses into reporting. The conversation dives into shared decision-making, a key principle in selecting between PPIs, topical steroids, elimination diets, and biologic therapy such as dupilumab. The faculty also review maintenance strategies, dilation techniques, response assessment timelines, and the potential for loss of therapeutic effect. Looking ahead, they highlight ongoing challenges in phenotyping, treatment personalization, and the expanding pipeline of novel agents. Whether you're a gastroenterologist, allergist, or APP managing EoE, this is a must-watch for optimizing care in this evolving space.

]]>Join Dr. Amit Patel and Dr. Gary Falk as they recap key highlights from the Eosinophilic Esophagitis (EoE) Disease State Summit, held live at GI ReConnect in Colorado. This expert-led discussion explores best practices in the evaluation, diagnosis, and management of EoE. The panel emphasizes updates from the ACG guidelines, including the importance of performing index endoscopy off therapy, standardized scoring tools like EREFS and the EoE Index of Severity (EoE-IS), and the nuanced role of histology in guiding treatment. They discuss differentiating EoE from GERD, appropriate biopsy practices, and integrating pathology features such as lamina propria fibrosis and microabscesses into reporting. The conversation dives into shared decision-making, a key principle in selecting between PPIs, topical steroids, elimination diets, and biologic therapy such as dupilumab. The faculty also review maintenance strategies, dilation techniques, response assessment timelines, and the potential for loss of therapeutic effect. Looking ahead, they highlight ongoing challenges in phenotyping, treatment personalization, and the expanding pipeline of novel agents. Whether you're a gastroenterologist, allergist, or APP managing EoE, this is a must-watch for optimizing care in this evolving space.

]]>4d154a1c-8481-4512-a463-2ad324d8f55fMon, 23 Jun 2025 00:00:00 -040036:16falsefullKOL Conversation on IBSKOL Conversation on IBSJoin Dr. Satish Rao, Dr. Andrea Shin, and Dr. Ali Rezaie, for a comprehensive roundtable discussion on the evolving landscape of irritable bowel syndrome (IBS), recorded live at GI ReConnect. This engaging conversation explores evidence-based management strategies for both IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D), covering dietary interventions, first-line therapies, FDA-approved medications such as linaclotide, lubiprostone, tenapanor, and rifaximin, and the growing role of neuromodulators in managing chronic pain. The faculty also discuss diagnostic tools including anorectal manometry and breath testing, the importance of identifying pelvic floor dysfunction and small intestinal bacterial overgrowth (SIBO), and the impact of psychological comorbidities, pelvic pain, and hormonal disorders on IBS outcomes. Additional highlights include commentary on emerging therapies such as microbiome-targeted interventions, fructo-oligosaccharide-based prebiotics, and investigational drugs like OPS-2071 and crofelemer. Emphasizing the importance of personalized care and multidisciplinary collaboration—including GI psychology, gynecology, and nutrition—this session offers clinicians practical insight into tailoring treatment plans to patient goals and symptom patterns while previewing the future of precision medicine in IBS care.

]]>Join Dr. Satish Rao, Dr. Andrea Shin, and Dr. Ali Rezaie, for a comprehensive roundtable discussion on the evolving landscape of irritable bowel syndrome (IBS), recorded live at GI ReConnect. This engaging conversation explores evidence-based management strategies for both IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D), covering dietary interventions, first-line therapies, FDA-approved medications such as linaclotide, lubiprostone, tenapanor, and rifaximin, and the growing role of neuromodulators in managing chronic pain. The faculty also discuss diagnostic tools including anorectal manometry and breath testing, the importance of identifying pelvic floor dysfunction and small intestinal bacterial overgrowth (SIBO), and the impact of psychological comorbidities, pelvic pain, and hormonal disorders on IBS outcomes. Additional highlights include commentary on emerging therapies such as microbiome-targeted interventions, fructo-oligosaccharide-based prebiotics, and investigational drugs like OPS-2071 and crofelemer. Emphasizing the importance of personalized care and multidisciplinary collaboration—including GI psychology, gynecology, and nutrition—this session offers clinicians practical insight into tailoring treatment plans to patient goals and symptom patterns while previewing the future of precision medicine in IBS care.

]]>ca5bc428-fc38-4c8e-8d68-f007764126bfMon, 23 Jun 2025 00:00:00 -040032:39falsefullKOL Conversation on CSID Paper ReviewKOL Conversation on CSID Paper ReviewAt GI ReConnect in Denver, Dr. Carlo Di Lorenzo, pediatric gastroenterologist at Nationwide Children’s Hospital, moderates an in-depth conversation with Dr. Ankur Chugh of Children’s Wisconsin and Dr. Khalil El-Chammas of Cincinnati Children’s, exploring the evolving landscape of Congenital Sucrase-Isomaltase Deficiency (CSID). Together, these experts discuss how CSID is increasingly recognized as a potential mimicker of IBS and other GI disorders, and how their own clinical experiences have shaped their understanding of when to test, how to interpret pan-disaccharidase deficiencies, and what treatment strategies—such as enzyme therapy and dietary exclusion—may be most effective. The conversation highlights diagnostic challenges, the importance of biopsy technique and sample size, and the need for more consistent, longitudinal research to guide clinical decision-making. Whether you’re a pediatric or adult GI specialist, this discussion provides actionable insights and expert perspectives on a condition that’s more prevalent than previously thought. Presented by the GI Health Foundation, this episode underscores the need for collaboration and education to improve outcomes in patients with chronic abdominal pain and suspected carbohydrate malabsorption.

]]>At GI ReConnect in Denver, Dr. Carlo Di Lorenzo, pediatric gastroenterologist at Nationwide Children’s Hospital, moderates an in-depth conversation with Dr. Ankur Chugh of Children’s Wisconsin and Dr. Khalil El-Chammas of Cincinnati Children’s, exploring the evolving landscape of Congenital Sucrase-Isomaltase Deficiency (CSID). Together, these experts discuss how CSID is increasingly recognized as a potential mimicker of IBS and other GI disorders, and how their own clinical experiences have shaped their understanding of when to test, how to interpret pan-disaccharidase deficiencies, and what treatment strategies—such as enzyme therapy and dietary exclusion—may be most effective. The conversation highlights diagnostic challenges, the importance of biopsy technique and sample size, and the need for more consistent, longitudinal research to guide clinical decision-making. Whether you’re a pediatric or adult GI specialist, this discussion provides actionable insights and expert perspectives on a condition that’s more prevalent than previously thought. Presented by the GI Health Foundation, this episode underscores the need for collaboration and education to improve outcomes in patients with chronic abdominal pain and suspected carbohydrate malabsorption.

]]>6cfe6b33-0c7b-4953-afb7-3eac159e1ebeMon, 23 Jun 2025 00:00:00 -040018:05falsefullInsights on Irritable Bowel SyndromeInsights on Irritable Bowel SyndromeIn this video, Jai Mirchandani, MD, of Allied Digestive Health sits down with Dr. Darren Brenner, Professor of Medicine and Gastroenterologist at Northwestern University, to discuss the latest approaches to diagnosing and managing irritable bowel syndrome (IBS). Dr. Brenner shares insights on the importance of correctly diagnosing IBS using Rome IV criteria, avoiding unnecessary testing, and distinguishing IBS from other gastrointestinal disorders. They explore how symptoms, alarm signs, and patient history guide diagnostic and treatment strategies. The discussion also covers evidence-based approaches to IBS management, including diet modifications like low FODMAP, brain-gut behavioral therapies, pharmacologic treatments, and personalized care plans based on patient preferences. Dr. Brenner emphasizes that IBS is not a single disorder but a collection of mechanisms leading to similar symptoms, highlighting the future of precision medicine in IBS care. Whether you're a healthcare professional or a patient seeking expert insights into IBS diagnosis and treatment, this conversation provides valuable, real-world strategies for effective management.

]]>In this video, Jai Mirchandani, MD, of Allied Digestive Health sits down with Dr. Darren Brenner, Professor of Medicine and Gastroenterologist at Northwestern University, to discuss the latest approaches to diagnosing and managing irritable bowel syndrome (IBS). Dr. Brenner shares insights on the importance of correctly diagnosing IBS using Rome IV criteria, avoiding unnecessary testing, and distinguishing IBS from other gastrointestinal disorders. They explore how symptoms, alarm signs, and patient history guide diagnostic and treatment strategies. The discussion also covers evidence-based approaches to IBS management, including diet modifications like low FODMAP, brain-gut behavioral therapies, pharmacologic treatments, and personalized care plans based on patient preferences. Dr. Brenner emphasizes that IBS is not a single disorder but a collection of mechanisms leading to similar symptoms, highlighting the future of precision medicine in IBS care. Whether you're a healthcare professional or a patient seeking expert insights into IBS diagnosis and treatment, this conversation provides valuable, real-world strategies for effective management.

]]>5170b406-d130-4326-b168-687f2b0d0181Mon, 16 Jun 2025 00:00:00 -040012:09falsefullWhat Are the Biggest Misconceptions of Low FODMAP Diet?What Are the Biggest Misconceptions of Low FODMAP Diet?In this video, registered dietitian nutritionist Robin Lynch from Allied Digestive Health addresses one of the most common questions about the low FODMAP diet: Is it really that restrictive? Robin explains that while many people assume the low FODMAP diet involves eliminating a vast number of foods, the reality is often much more manageable—especially with the right guidance. She highlights that the main restrictions typically involve wheat and dairy, leaving plenty of delicious, safe foods to enjoy. Robin discusses how individualized planning, including creating a personalized "yes list," can make the diet feel far less overwhelming and even easier for some patients, particularly picky eaters. By working closely with a dietitian experienced in low FODMAP education, patients can successfully navigate the elimination and reintroduction phases without unnecessary stress. If you're exploring the low FODMAP diet to manage IBS symptoms, this video offers realistic advice on how proper planning can make the journey much smoother—and far less restrictive than you might expect.

]]>In this video, registered dietitian nutritionist Robin Lynch from Allied Digestive Health addresses one of the most common questions about the low FODMAP diet: Is it really that restrictive? Robin explains that while many people assume the low FODMAP diet involves eliminating a vast number of foods, the reality is often much more manageable—especially with the right guidance. She highlights that the main restrictions typically involve wheat and dairy, leaving plenty of delicious, safe foods to enjoy. Robin discusses how individualized planning, including creating a personalized "yes list," can make the diet feel far less overwhelming and even easier for some patients, particularly picky eaters. By working closely with a dietitian experienced in low FODMAP education, patients can successfully navigate the elimination and reintroduction phases without unnecessary stress. If you're exploring the low FODMAP diet to manage IBS symptoms, this video offers realistic advice on how proper planning can make the journey much smoother—and far less restrictive than you might expect.

]]>bc1d9e5a-f377-4616-9656-2faf959635ceMon, 16 Jun 2025 00:00:00 -040001:27falsefullManagement of Heliocobacter pylori in North AmericaManagement of Heliocobacter pylori in North AmericaIn this video, Dr. William Chey, Chief of Gastroenterology and Hepatology at the University of Michigan, discusses the latest American College of Gastroenterology (ACG) clinical practice guidelines for the management of H. pylori infection. Speaking at the Allied GI Conference, Dr. Chey highlights why H. pylori remains a significant health concern in the U.S., affecting about one in three individuals and contributing to conditions like peptic ulcer disease and gastric cancer. He outlines key indications for H. pylori testing and treatment, including dyspepsia, unexplained iron deficiency anemia, and family exposure. Dr. Chey also addresses the growing issue of antibiotic resistance—particularly to clarithromycin and levofloxacin—and explains why certain empirical therapies are no longer recommended. He reviews first-line treatment regimens such as bismuth quadruple therapy, rifabutin triple therapy, and vonoprazan-based dual therapy, emphasizing the importance of confirming eradication after treatment. For clinicians seeking a practical, evidence-based approach to diagnosing, treating, and retesting for H. pylori infection, this presentation provides essential updates and expert guidance.

]]>In this video, Dr. William Chey, Chief of Gastroenterology and Hepatology at the University of Michigan, discusses the latest American College of Gastroenterology (ACG) clinical practice guidelines for the management of H. pylori infection. Speaking at the Allied GI Conference, Dr. Chey highlights why H. pylori remains a significant health concern in the U.S., affecting about one in three individuals and contributing to conditions like peptic ulcer disease and gastric cancer. He outlines key indications for H. pylori testing and treatment, including dyspepsia, unexplained iron deficiency anemia, and family exposure. Dr. Chey also addresses the growing issue of antibiotic resistance—particularly to clarithromycin and levofloxacin—and explains why certain empirical therapies are no longer recommended. He reviews first-line treatment regimens such as bismuth quadruple therapy, rifabutin triple therapy, and vonoprazan-based dual therapy, emphasizing the importance of confirming eradication after treatment. For clinicians seeking a practical, evidence-based approach to diagnosing, treating, and retesting for H. pylori infection, this presentation provides essential updates and expert guidance.

]]>29f83f4d-1b58-4b19-a4a3-2c790aa6ef5cMon, 16 Jun 2025 00:00:00 -040004:44falsefull